beta

AGEN

Agenus Inc.

Agen

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-06-2018 08-09-2018 05-07-2018 03-15-2018 11-07-2017 08-03-2017 05-04-2017
Actual EPS -0.29 -0.24 -0.42 -0.35 -0.37 -0.32 -0.18
Consensus EPS -0.25 -0.38 -0.28 -0.28 -0.37 -0.36 -0.32
Estimated EPS -0.25 -0.38 -0.28 -0.28 -0.37 -0.36 -0.32
Number of Estimates 2 1 2 2 2 2 2
EPS Surprise -$0.04 $0.14 -$0.14 -$0.07 $0.04 $0.14

Stats

Summary

Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Market Cap: 375 Million

Primary Exchange: NASDAQ Capital Market

Website: http://www.agenusbio.com

Shares Outstanding: 100 Million

Float: 92.6 Million

Dividend: 0.0 (0.0%)

Beta: 2.099262

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 9.25 Million

Ethical Flags

Animal testing

Longest drawdown: 878 trading days

From: 2015-06-17 To: 2018-12-11

Lowest Point:

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

via: PR Newswire at 2018-11-13 16:05:00:000

LEXINGTON, Mass. , Nov.13, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of … read more...

Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

via: PR Newswire at 2018-11-13 16:05:00:000

LEXINGTON, Mass. , Nov.13, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of … read more...

Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

via: PR Newswire at 2018-11-13 16:05:00:000

LEXINGTON, Mass. , Nov.13, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of … read more...

Agenus to Present at the 2018 Jefferies London Healthcare Conference

via: PR Newswire at 2018-11-13 11:30:00:000

LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, wi… read more...

Agenus to Present at the 2018 Jefferies London Healthcare Conference

via: PR Newswire at 2018-11-13 11:30:00:000

LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, wi… read more...

Agenus to Present at the 2018 Jefferies London Healthcare Conference

via: PR Newswire at 2018-11-13 11:30:00:000

LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, wi… read more...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

via: PR Newswire at 2018-11-06 17:42:00:000

LEXINGTON, Mass. , Nov. 6,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new data on several of its programs including AutoSy… read more...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

via: PR Newswire at 2018-11-06 17:42:00:000

LEXINGTON, Mass. , Nov. 6,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new data on several of its programs including AutoSy… read more...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

via: PR Newswire at 2018-11-06 17:42:00:000

LEXINGTON, Mass. , Nov. 6,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new data on several of its programs including AutoSy… read more...

Agenus (AGEN) CEO Garo Armen on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 12:24:16:000

Agenus (AGEN) Q3 2018 Earnings Conference Call November 6, 2018 8:30 A.M. ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Head of Clinical Development Christine Klaskin - Vice President of … read more...

Agenus (AGEN) CEO Garo Armen on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 12:24:16:000

Agenus (AGEN) Q3 2018 Earnings Conference Call November 6, 2018 8:30 A.M. ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Head of Clinical Development Christine Klaskin - Vice President of … read more...

Agenus (AGEN) CEO Garo Armen on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 12:24:16:000

Agenus (AGEN) Q3 2018 Earnings Conference Call November 6, 2018 8:30 A.M. ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Head of Clinical Development Christine Klaskin - Vice President of … read more...

Agenus misses by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-06 07:32:33:000

Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.29 misses by $0.04 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Agenus misses by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-06 07:32:33:000

Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.29 misses by $0.04 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Agenus misses by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-06 07:32:33:000

Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.29 misses by $0.04 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-11-06 07:30:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the third quart… read more...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-11-06 07:30:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the third quart… read more...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-11-06 07:30:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the third quart… read more...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-10-31 09:23:00:000

LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on … read more...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-10-31 09:23:00:000

LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on … read more...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-10-31 09:23:00:000

LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on … read more...

Agenus down 7% on PD-1/CTLA-4 program data

via: SeekingAlpha at 2018-10-22 12:10:57:000

Agenus ( AGEN -6.6% ) is down on below-average volume following the presentation of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus down 7% on PD-1/CTLA-4 program data

via: SeekingAlpha at 2018-10-22 12:10:57:000

Agenus ( AGEN -6.6% ) is down on below-average volume following the presentation of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus down 7% on PD-1/CTLA-4 program data

via: SeekingAlpha at 2018-10-22 12:10:57:000

Agenus ( AGEN -6.6% ) is down on below-average volume following the presentation of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

via: PR Newswire at 2018-10-20 07:30:00:000

LEXINGTON, Mass. , Oct. 20 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 2 , presented updated clinical data on its lead CTLA-4 and PD-1 programs today at th… read more...

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

via: PR Newswire at 2018-10-20 07:30:00:000

LEXINGTON, Mass. , Oct. 20 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 2 , presented updated clinical data on its lead CTLA-4 and PD-1 programs today at th… read more...

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

via: PR Newswire at 2018-10-09 09:00:00:000

LEXINGTON, Mass. , Oct. 9,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new clinical data on its lead CTLA-4 and PD-1 programs at the Europ… read more...

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

via: PR Newswire at 2018-10-09 09:00:00:000

LEXINGTON, Mass. , Oct. 9,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new clinical data on its lead CTLA-4 and PD-1 programs at the Europ… read more...

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

via: PR Newswire at 2018-10-09 09:00:00:000

LEXINGTON, Mass. , Oct. 9,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new clinical data on its lead CTLA-4 and PD-1 programs at the Europ… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Receives Milestone Payment from Incyte

via: PR Newswire at 2018-09-17 09:00:00:000

LEXINGTON, Mass. , Sept. 17, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today receipt of a cash milestone from Incyte for the initiation… read more...

Agenus Receives Milestone Payment from Incyte

via: PR Newswire at 2018-09-17 09:00:00:000

LEXINGTON, Mass. , Sept. 17, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today receipt of a cash milestone from Incyte for the initiation… read more...

Agenus Receives Milestone Payment from Incyte

via: PR Newswire at 2018-09-17 09:00:00:000

LEXINGTON, Mass. , Sept. 17, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today receipt of a cash milestone from Incyte for the initiation… read more...

Bulletproof Investing Performance Update, Week 41

via: SeekingAlpha at 2018-09-13 12:43:04:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 41 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Bulletproof Investing Performance Update, Week 41

via: SeekingAlpha at 2018-09-13 12:43:04:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 41 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Bulletproof Investing Performance Update, Week 41

via: SeekingAlpha at 2018-09-13 12:43:04:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 41 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Surviving A Bad Stock Pick: Agenus

via: SeekingAlpha at 2018-09-12 14:16:16:000

Image via Agenus's website . Surviving A Bad Pick In A Concentrated Portfolio Agenus ( AGEN ) was one of 5 underlying securities I included in a $100,000 hedged portfolio for my Bulletproof Investing subscribers on March 8th, and AGEN did terribly over the next several months, as you c… read more...

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

via: PR Newswire at 2018-09-05 19:34:00:000

LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ --AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa , Senior Dir… read more...

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

via: PR Newswire at 2018-09-05 19:34:00:000

LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ --AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa , Senior Dir… read more...

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

via: PR Newswire at 2018-09-05 19:34:00:000

LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ --AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa , Senior Dir… read more...

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

via: PR Newswire at 2018-09-04 09:57:00:000

LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and Extern… read more...

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

via: PR Newswire at 2018-09-04 09:57:00:000

LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and Extern… read more...

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

via: PR Newswire at 2018-09-04 09:57:00:000

LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and Extern… read more...

Agenus: Buy Or Sell?

via: SeekingAlpha at 2018-08-26 11:46:58:000

Agenus ( AGEN ) was founded in 1994 and is based in Lexington, MA. Shares have risen >30% last week since the idea was published to the subscribers of Vasuda Healthcare Analytics, marketplace service. Bull's case: (R&D pipeline, source company website) The company has a diverse… read more...

Agenus: Buy Or Sell?

via: SeekingAlpha at 2018-08-26 11:46:58:000

Agenus ( AGEN ) was founded in 1994 and is based in Lexington, MA. Shares have risen >30% last week since the idea was published to the subscribers of Vasuda Healthcare Analytics, marketplace service. Bull's case: (R&D pipeline, source company website) The company has a diverse… read more...

Agenus: Buy Or Sell?

via: SeekingAlpha at 2018-08-26 11:46:58:000

Agenus ( AGEN ) was founded in 1994 and is based in Lexington, MA. Shares have risen >30% last week since the idea was published to the subscribers of Vasuda Healthcare Analytics, marketplace service. Bull's case: (R&D pipeline, source company website) The company has a diverse… read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/21/2018)

via: SeekingAlpha at 2018-08-21 12:55:53:000

Gainers: TAT +21% . KOSS +21% . UXIN +18% . LLEX +17% . AGFS +16% . AGEN +16% . RNN +16% . BLFS +15% . PINC +15% . GSB +15% . Losers: SEAC -42% . NEWA -38% . SITO -17% . GRIN -13% . COCP -12% . DAKT -10% . COTY -10% . BOSC -10% . … read more...

Agenus earns second $4M milestone payment from Merck

via: SeekingAlpha at 2018-08-15 13:44:24:000

Agenus ( AGEN -4.7% ) announces that it has received a $4M milestone payment from Merck ( MRK +0.5% ) triggered by the initiation of a Phase 1 clinical trial of an undisclosed antibody discovered by Agenus. More news on: Agenus, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Agenus earns second $4M milestone payment from Merck

via: SeekingAlpha at 2018-08-15 13:44:24:000

Agenus ( AGEN -4.7% ) announces that it has received a $4M milestone payment from Merck ( MRK +0.5% ) triggered by the initiation of a Phase 1 clinical trial of an undisclosed antibody discovered by Agenus. More news on: Agenus, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Agenus earns second $4M milestone payment from Merck

via: SeekingAlpha at 2018-08-15 13:44:24:000

Agenus ( AGEN -4.7% ) announces that it has received a $4M milestone payment from Merck ( MRK +0.5% ) triggered by the initiation of a Phase 1 clinical trial of an undisclosed antibody discovered by Agenus. More news on: Agenus, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Agenus Receives Second Milestone Payment from Merck

via: PR Newswire at 2018-08-15 13:22:00:000

LEXINGTON, Mass. , Aug. 15, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Merck, known as MSD outside the United States and Can… read more...

Agenus Receives Second Milestone Payment from Merck

via: PR Newswire at 2018-08-15 13:22:00:000

LEXINGTON, Mass. , Aug. 15, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Merck, known as MSD outside the United States and Can… read more...

Agenus Receives Second Milestone Payment from Merck

via: PR Newswire at 2018-08-15 13:22:00:000

LEXINGTON, Mass. , Aug. 15, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Merck, known as MSD outside the United States and Can… read more...

Agenus (AGEN) CEO Garo Armen on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 14:32:06:000

Agenus (AGEN) Q2 2018 Results Earnings Conference Call August 9, 2018, 08:30 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Sunil Gupta - Head of Regulatory and Pharmacovigilance Christine Klaskin - VP of Finance Anal… read more...

Agenus (AGEN) CEO Garo Armen on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 14:32:06:000

Agenus (AGEN) Q2 2018 Results Earnings Conference Call August 9, 2018, 08:30 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Sunil Gupta - Head of Regulatory and Pharmacovigilance Christine Klaskin - VP of Finance Anal… read more...

Agenus (AGEN) CEO Garo Armen on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 14:32:06:000

Agenus (AGEN) Q2 2018 Results Earnings Conference Call August 9, 2018, 08:30 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Sunil Gupta - Head of Regulatory and Pharmacovigilance Christine Klaskin - VP of Finance Anal… read more...

Agenus up 2% premarket on Q2 results

via: SeekingAlpha at 2018-08-09 09:01:50:000

Agenus ( AGEN ) Q2 results : Revenues: $10.5M. More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Agenus up 2% premarket on Q2 results

via: SeekingAlpha at 2018-08-09 09:01:50:000

Agenus ( AGEN ) Q2 results : Revenues: $10.5M. More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Agenus up 2% premarket on Q2 results

via: SeekingAlpha at 2018-08-09 09:01:50:000

Agenus ( AGEN ) Q2 results : Revenues: $10.5M. More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Agenus beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-09 08:03:25:000

Agenus (NASDAQ: AGEN ): Q2 EPS of -$0.24 beats by $0.16 . More news on: Agenus, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Agenus beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-09 08:03:25:000

Agenus (NASDAQ: AGEN ): Q2 EPS of -$0.24 beats by $0.16 . More news on: Agenus, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Agenus beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-09 08:03:25:000

Agenus (NASDAQ: AGEN ): Q2 EPS of -$0.24 beats by $0.16 . More news on: Agenus, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 08:00:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the second quar… read more...

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 08:00:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the second quar… read more...

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 08:00:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the second quar… read more...

Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-08-02 14:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on … read more...

Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-08-02 14:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on … read more...

Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-08-02 14:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on … read more...

Agenus Illustrates Dilution And Non-Dilution Perils

via: SeekingAlpha at 2018-07-26 10:19:14:000

Agenus (AGEN) set a new 52-week low on July 24, closing at $1.94. It is also at a multi-year low. This small-cap biotech has a royalty interest in the new shingles vaccine Shingrix . It has a pipeline of immune-oncology drugs in the clinic, two licensed to Incyte (INCY). What went wrong and c… read more...

Agenus Illustrates Dilution And Non-Dilution Perils

via: SeekingAlpha at 2018-07-26 10:19:14:000

Agenus (AGEN) set a new 52-week low on July 24, closing at $1.94. It is also at a multi-year low. This small-cap biotech has a royalty interest in the new shingles vaccine Shingrix . It has a pipeline of immune-oncology drugs in the clinic, two licensed to Incyte (INCY). What went wrong and c… read more...

Agenus Illustrates Dilution And Non-Dilution Perils

via: SeekingAlpha at 2018-07-26 10:19:14:000

Agenus (AGEN) set a new 52-week low on July 24, closing at $1.94. It is also at a multi-year low. This small-cap biotech has a royalty interest in the new shingles vaccine Shingrix . It has a pipeline of immune-oncology drugs in the clinic, two licensed to Incyte (INCY). What went wrong and c… read more...

Agenus Appoints Regulatory and Clinical Heads

via: PR Newswire at 2018-07-16 08:37:00:000

LEXINGTON, Mass. , July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies 1 , today announced the appointment of I-O dr… read more...

Agenus Appoints Regulatory and Clinical Heads

via: PR Newswire at 2018-07-16 08:37:00:000

LEXINGTON, Mass. , July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies 1 , today announced the appointment of I-O dr… read more...

Agenus Appoints Regulatory and Clinical Heads

via: PR Newswire at 2018-07-16 08:37:00:000

LEXINGTON, Mass. , July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies 1 , today announced the appointment of I-O dr… read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Agenus to Webcast Annual Meeting of Stockholders

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites investors and the general public to attend its Annual Meeting of Stockholde… read more...

Agenus to Webcast Annual Meeting of Stockholders

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites investors and the general public to attend its Annual Meeting of Stockholde… read more...

Avrobio Aims For $75 Million U.S. IPO

via: SeekingAlpha at 2018-06-12 12:47:29:000

Quick Take Avrobio ( AVRO ) intends to sell shares of its common stock to raise $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing lentiviral-based gene therapies with the potential to treat rare diseases in a single dose. AVRO has a… read more...

Avrobio Aims For $75 Million U.S. IPO

via: SeekingAlpha at 2018-06-12 12:47:29:000

Quick Take Avrobio ( AVRO ) intends to sell shares of its common stock to raise $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing lentiviral-based gene therapies with the potential to treat rare diseases in a single dose. AVRO has a… read more...

Avrobio Aims For $75 Million U.S. IPO

via: SeekingAlpha at 2018-06-12 12:47:29:000

Quick Take Avrobio ( AVRO ) intends to sell shares of its common stock to raise $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing lentiviral-based gene therapies with the potential to treat rare diseases in a single dose. AVRO has a… read more...

Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

via: PR Newswire at 2018-06-12 08:30:00:000

LEXINGTON, Mass. , June 12, 2018 /PRNewswire/ --A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discov… read more...

Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

via: PR Newswire at 2018-06-12 08:30:00:000

LEXINGTON, Mass. , June 12, 2018 /PRNewswire/ --A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discov… read more...

Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

via: PR Newswire at 2018-06-12 08:30:00:000

LEXINGTON, Mass. , June 12, 2018 /PRNewswire/ --A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discov… read more...

Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-06-06 13:00:00:000

LEXINGTON, Mass. , June 6 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and External Affair… read more...

Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-06-06 13:00:00:000

LEXINGTON, Mass. , June 6 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and External Affair… read more...

Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-06-06 13:00:00:000

LEXINGTON, Mass. , June 6 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and External Affair… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

via: PR Newswire at 2018-05-17 13:37:00:000

LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-… read more...

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

via: PR Newswire at 2018-05-17 13:37:00:000

LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-… read more...

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

via: PR Newswire at 2018-05-17 13:37:00:000

LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-… read more...

Agenus -6.5% on at-the-market sales deal for 20M shares

via: SeekingAlpha at 2018-05-11 17:56:03:000

Biotech firm Agenus (NASDAQ: AGEN ) is 6.5% lower postmarket after a filing notes it's entered an at-the-market sales deal covering up to 20M shares. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus -6.5% on at-the-market sales deal for 20M shares

via: SeekingAlpha at 2018-05-11 17:56:03:000

Biotech firm Agenus (NASDAQ: AGEN ) is 6.5% lower postmarket after a filing notes it's entered an at-the-market sales deal covering up to 20M shares. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

via: SeekingAlpha at 2018-05-08 03:34:11:000

Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu… read more...

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

via: SeekingAlpha at 2018-05-08 03:34:11:000

Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu… read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-07 14:54:01:000

Agenus (AGEN) Q1 2018 Earnings Conference Call May 7, 2018, 11:00 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Christine Klaskin - VP of Finance Analysts Matt Philips - William Blair Presentation Operator … read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-07 14:54:01:000

Agenus (AGEN) Q1 2018 Earnings Conference Call May 7, 2018, 11:00 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Christine Klaskin - VP of Finance Analysts Matt Philips - William Blair Presentation Operator … read more...

Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston

via: PR Newswire at 2018-05-07 13:00:00:000

LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen , Ph.D., Chairman & CEO, and Jennifer Buell , Ph…. read more...

Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston

via: PR Newswire at 2018-05-07 13:00:00:000

LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen , Ph.D., Chairman & CEO, and Jennifer Buell , Ph…. read more...

Agenus reports Q1 results; provides milestones for 2018

via: SeekingAlpha at 2018-05-07 09:26:07:000

Agenus ( AGEN ) Q1 results : R&D Expense: $29.4M (-9.8%); SG&A: $10.7M (-7.8%); Net Loss: ($54.3M); Loss Per Share: ($0.53); Quick Assets: $52.3M (-13.1%). More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus reports Q1 results; provides milestones for 2018

via: SeekingAlpha at 2018-05-07 09:26:07:000

Agenus ( AGEN ) Q1 results : R&D Expense: $29.4M (-9.8%); SG&A: $10.7M (-7.8%); Net Loss: ($54.3M); Loss Per Share: ($0.53); Quick Assets: $52.3M (-13.1%). More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus misses by $0.23

via: SeekingAlpha at 2018-05-07 09:07:57:000

Agenus (NASDAQ: AGEN ): Q1 EPS of -$0.53 misses by $0.23 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus misses by $0.23

via: SeekingAlpha at 2018-05-07 09:07:57:000

Agenus (NASDAQ: AGEN ): Q1 EPS of -$0.53 misses by $0.23 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-05-07 09:00:00:000

LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the first quarter end… read more...

Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-05-07 09:00:00:000

LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the first quarter end… read more...

Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-05-03 09:00:00:000

LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday,… read more...

Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-05-03 09:00:00:000

LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday,… read more...

AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA

via: PR Newswire at 2018-05-01 08:00:00:000

LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz , Vice President, Head o… read more...

AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA

via: PR Newswire at 2018-05-01 08:00:00:000

LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz , Vice President, Head o… read more...

Evelo Biosciences To Raise $85 Million In IPO

via: SeekingAlpha at 2018-04-30 12:02:42:000

Quick Take Evelo Biosciences ( EVLO ) intends to raise $85 million in an IPO from the sale of its common stock. The company is developing a pipeline of monoclonal microbials that act on the gut-body complex to treat inflammatory diseases and cancers. EVLO is working in a nascent and … read more...

Agenus gets modust bump from Bristol-Myers' success with Opdivo/Yervoy in first-line NSCLC, shares up 3% premarket

via: SeekingAlpha at 2018-02-05 08:12:44:000

Agenus (NASDAQ: AGEN ) is up 3% premarket modestly higher volume in response to Bristol-Myers Squibb's announcement of positive results from a Phase 3 clinical trial evaluating the combination of Opdivo, an anti-PD-1 antibody, and Yervoy, an anti-CTLA-4 antibody, in first-line no… read more...

Agenus gets modust bump from Bristol-Myers' success with Opdivo/Yervoy in first-line NSCLC, shares up 3% premarket

via: SeekingAlpha at 2018-02-05 08:12:44:000

Agenus (NASDAQ: AGEN ) is up 3% premarket modestly higher volume in response to Bristol-Myers Squibb's announcement of positive results from a Phase 3 clinical trial evaluating the combination of Opdivo, an anti-PD-1 antibody, and Yervoy, an anti-CTLA-4 antibody, in first-line no… read more...

Agenus gets modust bump from Bristol-Myers' success with Opdivo/Yervoy in first-line NSCLC, shares up 3% premarket

via: SeekingAlpha at 2018-02-05 08:12:44:000

Agenus (NASDAQ: AGEN ) is up 3% premarket modestly higher volume in response to Bristol-Myers Squibb's announcement of positive results from a Phase 3 clinical trial evaluating the combination of Opdivo, an anti-PD-1 antibody, and Yervoy, an anti-CTLA-4 antibody, in first-line no… read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX